Clinical trials: Seasonal Rhinitis and/or Rhinoconjunctivitis
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600…
- Trial name
- NCT05540717
- Testing
- PQ Grass
- Where
- 102 sites in United States, Austria and 4 more
- Volunteers
- 555 people
- Sponsor
- Allergy Therapeutics
Seasonal Rhinitis and/or Rhinoconjunctivitis, Birch Pollen Allergy
SUBLIVAC® Birch PROBE Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in…
- Trial name
- NCT00932607
- Testing
- sublingual immunotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- HAL Allergy
Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for IgE mediated sensitization to grass pollen 4 concentrations of a modified pollen extract of Phleum pratense are applied to find out the optimum dose.
- Conditions
- Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen, Dose-Finding Study
- Trial name
- NCT01634958
- Testing
- Depigoid Phleum
- Where
- 2 sites in Germany
- Volunteers
- 308 people
- Sponsor
- Leti Pharma GmbH
Seasonal Allergic Rhinitis, Hay Fever
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
- Trial name
- NCT00574379
- Testing
- Bilastine
- Where
- 13 sites in United States
- Volunteers
- 805 people
- Sponsor
- Faes Farma, S.A.
Rhinitis, Allergic, Seasonal
An Exploratory Study of PQ Grass 27600 SU
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting.
- Trial name
- NCT04687059
- Testing
- PQ Grass
- Where
- 14 sites in United States, Germany
- Volunteers
- 119 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Seasonal Allergic Rhinitis, Hay Fever
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
The purpose of this study is to evaluate the relative efficacy of four dosing regimens of bilastine tablets versus placebo in subjects with SAR exposed in controlled ragweed pollen using the EEC model based on the mean change…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Rhinoconjunctivitis
- Trial name
- NCT00574210
- Testing
- Bilastine
- Where
- Canada
- Volunteers
- 502 people
- Sponsor
- Faes Farma, S.A.
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergy, Rhinitis
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.
- Conditions
- Allergy, Rhinitis, Rhinoconjunctivitis, Seasonal Asthma
- Trial name
- NCT01734265
- Testing
- Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml), Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Laboratorios Leti, S.L.
Hay Fever
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant
The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5…
- Trial name
- NCT01506375
- Testing
- gpASIT+TM, gpASIT+TM + adjuvant
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- BioTech Tools S.A.
Allergic Rhinoconjunctivitis, Chronic Urticaria
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population…
- Trial name
- NCT01081574
- Testing
- Bilastine
- Where
- 7 sites in Australia, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- Faes Farma, S.A.